What is this study trying to find out about lung cancer?

This study aims to collect real-world data on lung cancer patients in Algeria, including their clinical characteristics, tumor types, molecular markers, and treatment approaches. Researchers want to better understand how lung cancer is managed and the outcomes of treatments across the country. The study is sponsored by the Société Algérienne de Formation et de Recherche en Oncologie.

Who may be eligible for this lung cancer clinical trial?

Adults aged 18 years or older with a confirmed diagnosis of lung cancer, including NSCLC, SCLC, or carcinoid tumors, who are fully managed in oncology or pulmonology departments at certain hospitals may be eligible. Both men and women can join. Participants must not have been in this study before or be part of an interventional clinical trial. Please review eligibility criteria for more details.

Is there any cost to participate in this lung cancer clinical trial?

Study-related care, including data collection and all trial visits, is provided at no cost. However, personal travel and other expenses may vary and are not guaranteed to be covered by the study.

Actively Recruiting

Age: 18Years +

All Genders

ID07161882

Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer

Led by Société Algérienne de Formation et de Recherche en Oncologie · Updated on 2025-09-16

3750

Participants Needed

Research Sites

26 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are conducting a prospective, multicenter observational study called SAFRO 2202 ALG-Lung Cancer Registry to gather detailed information on lung cancer patients in Algeria. This study focuses on various types of lung cancer, including non-small cell lung cancer, small cell lung cancer, and carcinoid tumors. The goal is to collect real-world data on the epidemiology, clinical features, pathology, molecular markers, and treatment patterns to improve lung cancer care nationwide. The study involves adult patients aged 18 years and older who have been diagnosed with lung cancer at the time of enrollment or within the prior 12 months. Participants are managed fully within oncology or pulmonology departments at 21 public and university hospitals across Algeria. Data are collected during routine clinical care visits without any additional study-specific procedures or interventions. Information such as tumor histology, molecular profiles, staging, and treatment choices are recorded securely in an electronic case report form. During the study, researchers will track clinical outcomes including treatment toxicities, response rates, progression-free survival, time to treatment discontinuation, and overall survival. Data collection aligns with standard care and includes demographic details, medical history, risk factors, and performance status. The study plans to enroll about 1,500 patients per year over 30 months, with each patient followed for at least 12 months to support future health planning and lung cancer management improvements in Algeria.

CONDITIONS

Brief Title

ALG-LungCancerRegistry (SAFRO2202)

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 years or older
Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)
Diagnosed at the time of inclusion or within the previous 12 months
Fully managed in oncology or pulmonology departments at one of the 21 participating public or university hospitals
Signed informed consent obtained

You will not qualify if you...

Prior enrollment in this study
Participation in an interventional clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - At least 12 months

Participants who undergo routine lung cancer care are observed. Clinical, pathological, molecular, and treatment-related data are collected during routine medical care with no additional study visits required.

Visits as part of routine clinical care